生血宁治疗慢性肾脏病患者贫血的疗效观察

Effect of Shengxuening in the treatment of renal anemia of CKD patients

目的观察生血宁治疗慢性肾脏病（CKD）3—4期患者肾性贫血的疗效。方法收集2012年1月至2014年12月在无锡市锡山人民医院肾内科住院治疗的CKD患者的临床资料，根据其使用治疗贫血药物不同将其分为A、B两组，A组予生血宁片口服，B组予右旋糖酐铁片口服，两组同时接受重组人促红细胞生成素（rhEPO）的治疗，疗程12周（随访至12周）。观察治疗前后患者血红蛋白（Hb）、血清铁蛋白（SF）、转铁蛋白饱和度（TSAT）的变化及重组人促红素（rhEPO）的用量，并观察基础指标血清白蛋白（ALB）、尿素氮（BUN）、肌酐（SCr）、C反应蛋白（CRP）的变化。采用SPSS17．0软件包进行统计学分析。结果治疗后两组患者的贫血均有改善。A组Hb、SF、TSAT上升的幅度高于B组，差异有统计学意义（P〈0．05）。A组rhEPO用量少于B组，差异有统计学意义（Z=3．058，P〈0．05）。治疗后两组‘肾功能和CRP均无明显变化（P〉0．05），A组ALB水平较治疗前明显升高，差异有统计学意义（t=2．811，P〈0．05），A组未见明显不良反应。结论生血宁可改善铁代谢，治疗CKD患者肾性贫血安全有效，并可以减少rhEPO的用量。

Objective To observe the effects of Shengxuening in treatment of patients with chronic kidney disease （CKD） stage Ⅲ-Ⅳ complicated with renal anemia. Methods 96 enrolled CKD patients with moderate anemia were randomly divided into two groups： group A was given oral Shengxuening tablets, and group B given oral iron dextran tablets; and both groups also received recombinant human erythropoietin （rhEPO） for 12 weeks. Before and after the treatment, the patients were observed for the changes in hemoglobin （ Hb）, serum ferritin （ SF）, transferrin saturation （ TSAT）, serum albumin （ ALB）, blood urea nitrogen （BUN）, serum creatinine （SCr）, C-reactive protein （CRP）, and EPO dosage. The follow-up was made for half a year. The SPSS 17.0 software was used for statistical analysis. Results The anemia was improved in both of the two groups. The speed and amplitude of increase in Hb, SF, and TSAT of group A were greater than those of group B （P 〈 0.05）. The usage of rhEPO in group A was less than that in group B （P 〈 0.05）. After the treatment, renal function and CRP did not change significantly in both groups （ P 〉 0.05） ; but the ALB level in group A was higher than that in group B （P 〈 0.05）. Group A had no obvious adverse reactions. The improvement in anemia after follow-up for half a year was relatively stable. Conclusion Shengxuening could improve iron metabolism, was effective and safe in the treatment of renal anemia of patients with CKD, and could reduce the useage of rhEPO.